News and Trends 31 Oct 2016 Meet the Jellyfish Medtech seeking to disrupt the Collagen Market Jellyfish are a source of collagen: this is the idea behind the winner of Boost Cymru, a competition of the Life Sciences Hub Wales. We had a chat with Andrew Mearns-Spragg, CEO of Jellagen, about this promising startup. The jellyfish already has a place in Biotech’s hall of fame as the source of the gene for […] October 31, 2016 - 5 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 29 Oct 2016 Aliens in the Cornfield: The Borg Are Taking over Nebraska The assimilation of the human race has begun! A Star Trek nightmare is coming true, as biohackers recruit piercing artists to build human-based Borg. Similar to the Borg’s obsession with perfecting biological life through machinery, biohackers are driven to make human life easier with technological implants. The first trials have already begun, as some biohackers have […] October 29, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […] October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 Meet Spain’s Gold BIOMEDAList in Celiac Disease This week we’re heading South back to my hometown, Sevilla! Even well into October, the skies are clear and the sun is shining while we drop by Biomedal, this week’s Biotech. City: Sevilla, Spain Founded: 2000 Employees: 31 Financial data: €2.5M in sales with an impressive 60% growth in the last year Mission: The company has three […] October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 UPDATE: Immuno-Oncology Combo works on Lung Cancer Regardless of PD-L1 Type AstraZeneca’s MedImmune (UK) has published phase Ib study results in The Lancet Oncology. These showed anti-tumour activity of a combination of investigational antibodies in patients with lung cancer. The trial considered patients undergoing treatment with durvalumab and tremelimumab, to see whether the drug combo could act therapeuticaly against locally advanced or metastatic non-small cell lung cancer (NSCLC), irrespective of […] October 28, 2016 - 2 minutesmins - By Dani Bancroft Share WhatsApp Twitter Linkedin Email
Inside Labiotech 28 Oct 2016 Santé, Labiotech.eu is now 2 years old! (and what a journey so far) Yes, it’s been already 2 years since Joachim and I moved to Berlin to work full-time on changing the media landscape of Biotech. And this second year has just been exceptional: we are now the leading digital media in Europe with 50k monthly visitors, a team of almost 10 people, solid investors, and over 50 customers. […] October 28, 2016 - 5 minutesmins - By Philip Hemme Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2016 €36M Fundraising to Sequence the Genome of Ireland Genomics Medicine Ireland (GMI) has raised €36M ($40M) in series A to sequence the genome of the Irish and use the info for the development of new drugs and diagnostics. Genomics Medicine Ireland (GMI) is committed to revolutionizing health care with whole-genome sequencing. The company just raised €36M ($40M) in Series A that will be used to […] October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2016 Boehringer enters the Biosimilar War against Blockbuster Humira Boehringer Ingelheim just announced positive Phase III results for its Humira biosimilar. The company is joining many others in the fights to take a bite of the huge market that will be open for access when patents expire later this year. AbbVie’s Humira (adalimumab) is the best selling biological, with a jaw-dropping €13B ($14B) in […] October 27, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2016 UPDATE: Future of CAR-T shaken by Novartis R&D Shuffle After a promising kick off, Novartis is raising doubts about the future of its CAR-T program with its decision to dissolve and reintegrate the cell and gene therapy division into its immuno-oncology effort. Yes, you read that correctly: despite exciting progress by Novartis’s CAR-T therapy program, the company is reportedly disbanding the cell and gene therapy […] October 27, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 27 Oct 2016 Oxitec scales up Mosquito production with a new Factory in Brazil Since Brazil became the first country in the world to deploy GM mosquitos, Oxitec has opened a factory there to produce its Friendly Aedes aegypti. Oxitec has opened a large-scale mosquito factory in Piracicaba, Brazil, to scale up production of their Friendly Aedes aegypti mosquitos. These mosquitos are effectively sterilized so they don’t transmit infectious […] October 27, 2016 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Proteins can now Sing about their Anomalies to help cure Diseases Researchers are generating melodies from proteins’ structures. It could be used to understand protein folding and anomalies that contribute to disease. Protein folding is an infamously difficult phenomenon to understand and predict from sequence data. A collaboration between a resident composer at the University of Tempere in Finland and a scientist at the Francis Crick […] October 26, 2016 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 26 Oct 2016 Can this new Antibody-Drug Conjugate Collaboration make it to the Top? Nordic Nanovector is collaborating with Heidelberg Pharma to access the promising antibody-drug conjugate (ADC) technology. However, can it really take on the strong competition? Nordic Nanovector develops antibody-radionuclide conjugates (ARCs) to treat Non-Hodgkin Lymphoma (NHL) and other blood cancers. Today, the company has announced a collaboration with Wilex’ subsidiary Heidelberg Pharma to incorporate antibody-drug conjugates (ADCs) […] October 26, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email